Dynavax Technologies is a fully-integrated biopharmaceutical company focused on leveraging the power of the body’s innate and adaptive immune responses through Toll-like Receptor (TLR) stimulation. Our company is dedicated to developing and commercializing innovative vaccines that modulate the immune system to prevent disease. We are the maker of the only 2-dose Hepatitis B vaccine for adults: Heplisav-B, where the series is completed in just one month. Heplisav-B improves efficiency, outcomes, and can reduce overall spend vs. that of the traditional 3-dose option, which is proven in head-to-head trials to be less effective and has significantly lower completion rates. Our innovative vaccine is more effective in any adult population, especially those who have a diminished response to hepatitis B vaccines (i.e. chronic liver disease, diabetes, high BMIs, HIV, injection drug users, smokers, etc.).
“Liver cancer is the 3rd deadliest cancer worldwide, with 5 year survival rates of only 15%. Hepatitis B causes up to 50% of hepatocellular carcinomas as well as 15% of cirrhosis diagnoses. Approximately 78% of hepatocellular carcinoma are attributable to infections with hepatitis B, therefore, it is essential to have a highly effective preventative option to save lives.”
For more information please contact:
Commercial Region Leader - AZ, AR, CO, ID, NM, NV, OK, TX & UT